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Abstract – The authors have discussed the chemical struture, 
major biochemical characteristics and biological significance 
of polyunsaturated fatty acids. Their particular focus was on 
the role of -3 and -6 acids in physiological processes and 
pathology development in human organism. 
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Streszczenie – Autorzy przedstawili budowę chemiczna, waż-
niejsze cechy biochemiczne oraz znaczenie biologiczne wie-
lonienasyconych kwasów tłuszczowych. Szczególnie skupili 
się na roli -3 i -6 kwasów w procesach fizjologicznych i w 
narastaniu patologii w organizmie człowieka. 
 
Słowa kluczowe – -3 i -6 wielonienasycone kwasy tłusz-
czowe, cechy biochemiczne, rola fizjologiczna, konsekwencje 
niedoboru. 
 
Author Affiliations: 
1. Collegium Masoviense - College of Health Sciences, Żyrar-
dów 
2. Faculty of Health Sciences, Collegium Medicum, Jagielloni-
an University 
3. Ivano-Frankivsk Medical Institute, Ukraine 
 
Authors’ contributions to the article:  
A. The idea and the planning of the study  
B. Gathering and listing data  
C. The data analysis and interpretation  
D. Writing the article  
E. Critical review of the article  
F. Final approval of the article  
 
Correspondence to: 
 
Prof. Zbigniew Kopański MD, PhD, Collegium Masoviense - 
College of Health Sciences, Żyrardów, G. Narutowicza 35 Str., 
PL-96-300 Żyrardów, Poland, e-mail: zkopanski@o2.pl 
 
 
 
 
 
 
 
I. INTRODUCTION 
 
n human organism, fatty acids predominantly have an 
esterified form and appear in natural fats and oils. 
Nevertheless, they are transported in the serum as non-
esterified free fatty acids. Fatty acids in natural fats are 
usually a derivative of unbranched hydrocarbon chains 
with a hydrophobic methyl group at one end and a hydro-
philic carboxyl group at the other (fig. 4).  The methyl end 
of the molecule is referred to as -end, whereas the car-
boxyl group is at the -end. The names of acids are derived 
from the omega numbering system. In this system, carbon 
atoms are numbered starting at the methyl end. The proper-
ties of selected fatty acids are dependent on the length of 
the carbon chain as well as on the number and location of 
double bonds. Fatty acids can be divided into saturated (no 
double bonds), monounsaturated (one double bond) and 
polyunsaturated ones ( 2 bonds) [1-4]. 
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-6   Arachidonic acid    (C20:4, -6) 
 
 
 
 
-3  Eikosapentaenoic acid (C20:5, -3) 
 
 
 
 
-3  Docosahexaenoic acid (C20:5, -3) 
 
         Figure 4. Major fatty acids [ 4 ] 
 
Explanation: * The first number is the amount of carbon 
atoms; the colon is followed by the number of double 
bonds. The data after the comma is the location of the 
first double bond, starting the count at the methyl end. 
 
Polyunsaturated fatty acids (PUFAs) can be divided into 
two subgroups: -3 and -6. In -3 PUFAs, the first 
double bound is located after the third carbon atom (C-3) 
(table 3), whereas in -6 PUFAs it is after C-6. -3 and 
-6 acids are considered essential fatty acids as human 
organism cannot synthesise them and they need to be 
provided in food [3,4].  
 
Table 3. -3 polyunsaturated fatty acids of physiolog-
ical significance [5] 
 
Symbol 
liczbowy 
kwasu* 
Systematic name Common name 
C18:3,  
-3 
6,12,15- octadecatrienoic 
acid 
Alpha-linolenic acid 
C20:5,  
-3 
5,8,11,14,17- eicosapentae-
noic acid 
Timnodonic acid 
C22:5,  
-3 
7,10,13,16,19- docosapen-
taenoic acid 
Clupanodonic acid 
C22:6,  
-3 
4,7,10,13,16,19- docosahex-
aenoic acid 
Cervonic acid 
 
Explanation: * The first number is the amount of 
carbon atoms; the colon is followed by the number of 
double bonds. The data after the comma is the loca-
tion of the first double bond, starting the count at the 
methyl end. 
 
Alpha-linolenic acid is transformed during dehydrogena-
tion and chain lengthening to fatty acids of 20 and 22 
carbon atoms, which are referred to as long chain essen-
tial fatty acids [Gerster (1998)]. The one of most biolog-
ical significance among them is eicosapentaenoic acid – 
a precursor to Series 3 prostaglandins (PG3), thrombox-
ane (TX3) and leukotriene (fig. 5). PG3 and TX3 inhibit 
the arachidonate release from phospholipids as well as 
PG2 and TX2 formation. PG3 has stronger antiaggregatory 
effect on platelets as compared to PGI2, whereas TXA3 is 
a weaker thrombocyte aggregation factor than TXA2. As 
a result, the dominant biological effect of eicosanoids 
from -3 PUFAs is platelet aggregation and anti-
inflammatory effects [3-9].  
 
 
 
Figure 5. The course of desaturation and lengthen-
ing -3 polyunsaturated fatty acids and the formation 
of their eicosanoids [3] 
 
II. THE ROLE OF -3 POLYUNSATURATED 
FATTY ACIDS IN PHYSIOLOGY AND 
PATHOLOGY 
 
-3 PUFAs are, similarly to other kinds of fatty acids, 
not only an energy source but also a carrier of lipid solu-
ble vitamins. What is more, they participate in the bio-
synthesis of prostanoids and transportation as well as 
oxidation of cholesterol. Additionally, they perform 
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structural functions as they are one of the components of 
membrane lipids [3,6,8,10,11,12].  
One of the biologically relevant properties of -3 
PUFAs is related to their anti-coagulant effects [ 3 ]. For 
instance: eicosapentaenoic acid inhibits the synthesis of 
thromboxane A2 and prostaglandin that causes platelet 
aggregation and vasospasms [4,5,12-15]. The -3 acids 
also lower the concentration of fibrinogen and increase 
the concentration of tissue plasminogen activator [4]. 
What is more, the acids in this group lower the concen-
tration of blood triglycerides [4,5,14-16]. They also af-
fect the blood cholesterol level. However, the biological 
effects they have are interpreted in various ways. Some 
authors [2] report the increase in the HDL2 concentration 
after the intake of -3 PUFAs, whereas others [15,16] 
confirm the decrease in  HDL3 containing substantial 
amounts of triglycerides. There are also reports claiming 
that -3 PUFAs may increase the susceptibility of LDL 
cholesterol to oxidation. Some indicate that -3PUFAs 
have hypotensive effects [17]. Recently, there has been a 
lot of interest in potentially antiarrhythmic effects of 
these fatty acids. It is believed that -3 PUFAs stabilise 
the electrical activity of cardiac muscle cells by blocking 
the ion channels, prolonging the relative refractory peri-
od [10,18]. Also, their positive effects on endothelium 
are emphasised [18].  The studies of animal models 
showed that -3 PUFAs have antiaherogenic effects (ta-
ble 4). These properties, however, are retained mainly by 
the acids of marine origin [3,19,20]. 
 
Table 4. The impact of -3 PUFAs on mediators of ath-
erosclerosis [3-5,21] 
Factor Function The impact of -3 
PUFAs 
Arachidonic acid 
The precursor of eico-
sanoids, its effect is plate-
let aggregation 
↓ 
Thromboxane A2 
Platelet aggregation, 
vasoconstriction 
↓ 
Prostacyklin 
Prevents from platelet 
aggregation, vasodilata-
tion 
↑ 
Tissue plasminogen 
activator 
Intensifies fibrinolysis ↑ 
Fibrinogen Coagulation factor ↓ 
Platelet activation 
factor 
Activates platelets and 
leukocytes 
↓ 
Platelet-derived 
growth factor 
A chemoatractant and a 
mitogen of smooth mus-
cles and macrophages 
↓ 
Endothelium-derived 
relaxing factor 
Decreases the vasospastic 
artery reaction 
↑ 
Triglycerides and 
chylomicrons 
Participating in postpran-
dial lipidemia 
↓ 
High-density lipopro-
teins 
Decrease the risk of is-
chaemic heart disease 
↑ 
Lipoprotein (a) Atherogenic Lipoprotein ↓ 
Explanation:           - decrease          - increase 
Certain works also emphasise a negative impact of 
PUFAs on human organism. That is predominantly con-
nected with the promotional role of linoleic acid and its 
20-carbon homologue - arachidonic acid in neoplastic 
processes (fig. 6) [3,5,22]. 
The interest in the role of 20-carbon unsaturated fatty 
acids in carcinogenesis resulted from the observation of 
increased prostaglandin concentration in neoplasms in 
humans. Presently, it is acknowledged that the inhibition 
or stimulation of carcinogenesis is dependent on the type 
of prostaglandin, its concentration and the type of the 
target cell (neoplasm type) [3-5]. For instance, PGE2 and 
PGD2 have inhibitory effects, whereas TXA2 and malo-
nylodialdehyde are stimulating factors for cancer growth 
[3].  
Presently, the participation of PUFAs in carcinogenesis 
in human organism is associated predominantly with a 
regulatory (agonistic or antagonistic) influence of the 
acids on the receptors with their own tyrosine kinase. 
The effect of -3 PUFAs most probably consists in 
blocking the receptors, hence the increase in the concen-
tration of the acids may contribute to cancer growth pre-
vention [3-5,15].  
The receptors of this group include epidermal growth 
factor, EGF and proto-oncogenes C-erbB2 (neu) and c-
erbB3 [2-5]. 
The transmission of the signal from the receptor to tyro-
sine kinase is a multistage process. After cytokine (or an 
antagonist) is bonded, the receptor dimerises and under-
goes autophosphorylation. After that, the kinase which is 
an integral part of the receptor phosphorylates proteins 
with homological sections with c-Src (SH2), which con-
stitute a beginning to several signal transduction path-
ways to the nucleus (fig. 8).  
The family of cytoplasmic c-Src tyrosine kinases is con-
stituted by at least nine proteins of similar structure. The 
proteins stimulate the c-Ras signal pathway on one side 
and phosphatidylinositide 3-kinase one the other. Ras 
protein counters the MAP (mitogen activated protein) 
kinases and serine/threonine kinases cascade. These ki-
nases, coded by the c-raf gene, participate in the trans-
mission of mitogen signal from membrane receptor to 
nucleus. Presently, it is acknowledged that Ras protein 
plays a major part in neoplastic transformation also by 
means of activating other oncogenes, including: Pim-1, 
Mos, Raf, Myc, Myh, Fos, Jun, ErbA, Ets [15,23,24]. 
What is more, the risk of cancer is increased by the fact 
that PUFAs  are likely to undergo oxidation processes as 
a result of which hydroxides, endogenic peroxides, epoxy 
compounds and free radicals are formed. These com-
pounds may damage the cell membrane structure, trigger-
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ing the release of ions stored in cell organelles (fig. 9). 
The ions catalyse the formation of new radicals, which 
continue to destroy the lipid structure. The radicals re-
leased may also damage the DNA structure and lead to 
the formation of mutagenic and carcinogenic products 
[5]. 
Additionally, PUFAs increase the fluidity and permeabil-
ity of cell membranes, facilitating carcinogenic com-
pounds to penetrate the cells [2,3]. 
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nucleus directly. 
 
● JOURNAL OF PUBLIC HEALTH, NURSING AND MEDICAL RESCUE ● 2/2014 ● 
 
21 ● JOURNAL OF PUBLIC HEALTH, NURSING AND MEDICAL RESCUE ● No. /2014 ● 
 
 
 
[5] Hansonn HA. Physiology in Health and Disease. Phil-
adelphia; Saunders 2012. 
[6] Nowak J, Zawilska J (red.). Receptory - struktura, cha-
rakterystyka, funkcja. Warszawa; Wydawnictwo Na-
ukowe PWN, 1997. 
[7] Meydani M.  Nutrition interventions in aging and age-
associated disease. Ann N Y Acad Sci; 2001, 928: 
226 – 235 
[8] Yehuda S. Omega-6/Omega-3 ratio and brain related 
functions. World Rev Nutr Diet; 2003, 92: 37–56. 
[9] Mahan LK, Escott-Stump S.  Food and NutritionTher-
apy.  St. Louis; Saunders Elsevier 2012. 
[10] Fetterman JW, Zdanowicz MM. Therapeutic poten-
tial of n-3 polyunsaturated fatty acids in disease. Am 
J of Health-Syst Pharm, 2009; 66 (13): 1169-79. 
[11] Johnson M, Östlund S, et al. Omega-3/Omega-6 fatty 
acids for attention deficit hyperactivity disorder. J 
Atten Dis; 2009, 12 (5): 394-401.  
[12] Lorgeril M, Salen P, Defaye P, Rabaeus M. Recent 
findings on the health effects of omega-3 fatty acids 
and statins and their interactions: do statins inhibit 
omega-3? BMC Med; 2013, 11 (5): 1-40.  
[13] Bucher H.C, Hengstler P, Schindler C, Meier G. N-3 
polyunsaturated fatty acids in coronary heart disease: 
a meta-analysis of randomized controlled trials. Am J 
Med; 2002, 112: 298-304.  
[14] Bjerve KS, Brubak AM. N-3 fatty acids - essential 
fatty acids with important biological effects, and se-
rum phospholipids fatty acids as markers of dietary 
n-3 fatty acids intake. Am J Clin Nutr; 1993, 5(S): 
801-805. 
[15] Gogus U, Smith C. n-3 Omega fatty acids: a review 
of current knowledge. Int J Food Sci Technol; 2010, 
45: 417-436.  
[16] Banning M. The role of omega-3-fatty acids in the 
prevention of cardiac events. Br J Nurs; 2005, 25; 
503-508.  
[17] Cabo J, Alonso R, Mata P. Omega-3 fatty acids and 
blood pressure. Br J Nutr; 2012; 107:195-200. 
[18] MacLean C, et al.  Effects of omega-3 fatty acids on 
cancer risk. JAMA; 2006, 295 (4): 403-415. 
[19] Ciborowska H, Rudnicka A. Dietetyka żywienie 
zdrowego i chorego człowieka. Warszawa; Wydaw. 
Lekarskie PZWL, 2007. 
[20] Gwęcki J, Mossor-Pietraszewska T. Kompedium 
wiedzy o żywności, żywieniu i zdrowiu. Warszawa; 
Wydawnictwo Naukowe PWN, 2004. 
[21] Bloch MH, Hannestad J. Omega-3 fatty acids for the 
treatment of depression: systematic review and meta-
analysis. Mol Psychiatry; 2012, 17 (12): 1272–1282. 
[22] Maillard V,  Bougnoux P,  Ferrari P, et al. N-3 and 
N-6 fatty acids in breast adipose tissue and relative 
risk of breast cancer in a case-control study in Tours, 
France. Int J Cancer; 2002, 98 ( 1 ): 78 - 83. 
[23] Hall GM. Fish processing technology. New York ; 
Chapman&Hall 2012. 
[24] Apte SA, Cavazos DA, Whelan KA, Degraffenried 
LA. A low dietary ratio of omega-6 to omega-3 fatty 
acids may delay progression of prostate cancer. Nutr 
Cancer ;2013, 65 (4): 556-62.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
